

## 2010 Genitourinary Cancers Symposium Disclosure

In compliance with the ASCO Conflict of Interest Policy and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, abstract authors, and faculty who participate in any ASCO- or co-sponsored meeting must disclose financial interests and other relationships with entities that have an investment, licensing, or other commercial interest in the subject matter under consideration in their abstract or presentation. Author and faculty disclosures may be published in ASCO publications where appropriate.

Authors and faculty will be asked to disclose financial interests and other relationships in the following categories:

### Items Requiring Disclosure

#### **A. Employment or Leadership Position**

Any full- or part-time employment or service as an officer or board member for an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed.

#### **B. Advisory Role**

Consultant or advisory arrangements with an entity having an investment, licensing, or other commercial interest in the subject matter under consideration must be disclosed if consultation was performed or payments made for such consultation within 2 years of the activity or subject matter in question.

#### **C. Stock Ownership**

Any ownership interest (except when invested in a diversified fund not controlled by the covered individual) in a start-up company, the stock of which is not publicly traded, or in any publicly traded company must be disclosed if the company is an entity having an investment, licensing, or other commercial interest in the subject matter under consideration.

#### **D. Honoraria**

Honoraria are reasonable payments for specific speeches, seminar presentations, or appearances. Disclosure of honoraria is required when paid directly to the covered individual by an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and when provided within 2 years of the activity or subject matter in question.

#### **E. Research Funding**

All payments associated with the conduct of the clinical research project in question must be disclosed if provided by the trial sponsor or agents employed by the sponsor.

#### **F. Expert Testimony**

Provision of expert testimony must be disclosed when the testimony relates to the subject matter under consideration.

#### **G. Other Remuneration**

The value of trips, travel, gifts, or other in-kind payments not directly related to research activities must be disclosed if received from an entity having an investment, licensing, or other commercial interest in the subject matter under consideration and when received within 2 years of the activity or subject matter in question. These payments exclude research-related costs and travel.

## 2010 Faculty/Program and Steering/News Planning Committee Disclosure Index

The 2010 Genitourinary Cancers Symposium Program Committee has reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict where they exist. Financial relationships reported by members of the 2010 Genitourinary Cancers Symposium Program and Steering Committees are also provided below. During all phases of planning for the Symposium, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate. Program and Steering Committee members are indicated with a dagger (†); News Planning Committee members are indicated with a double dagger (‡). Relationships are considered self-held and compensated unless otherwise noted. Relationships in the first column are considered employment relationships unless designated as a leadership position. I – Immediate Family Member; B – Myself and Immediate Family Member; U – Uncompensated; L – Leadership Position.

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Atkins, Michael B.		Antigenics; Aveo; Bayer; Bristol-Myers Squibb; Genentech; Novartis; Onyx; Pfizer					
Bajorin, Dean F.†		Bristol-Myers Squibb; GPC Biotech; Lilly; Pfizer		Lilly	Bristol-Myers Squibb; Genentech; GPC Biotech; Lilly; Pfizer		
Bellmunt, Joaquim†		Bayer; Pfizer; Wyeth		Bayer; Pfizer			
Blute, Michael L.							
Bosl, George J.							
Boyle, Peter							
Brawley, Otis W.		GlaxoSmithKline	GE Healthcare; Theragenics				
Carroll, Peter R.							
Chen, David Y. T.							
Cheng, Christopher W.†							
Cho, Daniel C.							
Choueiri, Toni K.		Bayer; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer					
deVere White, Ralph W.†							
DiPaola, Robert S.†							
Divgi, Chaitanya R.		Wilex					
Drake, Charles G.		Amplimmune; Bristol-Myers Squibb; Dendreon; Medarex	Amplimmune				Medarex
Gelmann, Edward P.							
Gervais, Debra					Covidien		
Gomella, Leonard G.†		GlaxoSmithKline; sanofi-aventis; Watson		Watson	Dendreon; GlaxoSmithKline; Photocure		

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Grignon, David J.							
Haas, Naomi B.†	Nereus Pharmaceutical (I); PrECOG (I); TetraLogic Pharmaceuticals (I)	AstraZeneca (I); Nereus Pharmaceutical (I); PrECOG (I); Tetralogic Pharmaceuticals (I); Willex Oncology	Tetralogic Pharmaceuticals (I)	Bayer (I); Bristol-Myers Squibb (I); Genentech (I); MethylGene (I)	AstraZeneca (I); Bayer (B); Bristol-Myers Squibb (I); ImClone Systems (I); Genentech (I); GlaxoSmithKline (I); Kosan Biosciences (I); Merck (I); MethylGene (I); Novartis (I); Pfizer (B); Plexxicon (I); Roche (I); sanofi-aventis (I)		
Harisinghani, Mukesh G.		Profound Medical (U)					
Heath, Elisabeth I.					Amgen; AstraZeneca; BiPar Sciences; Bristol-Myers Squibb; GlaxoSmithKline; Pfizer; Seattle Genetics; Zymogenetics		
Herr, Harry W.†							
Hinshaw, J. Louis†			Collectar				
Hudes, Gary R.		Aveo; Genentech; GlaxoSmithKline; Merck; Novartis; Pfizer; Wyeth		Pfizer			
Hussain, Maha H.†		Ascenta Therapeutics; Ferring; Lilly			Abraxis BioScience; ImClone Systems; Millennix; Pfizer		
Hutson, Thomas E.		Bayer; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer; Wyeth		Bayer; Genentech; GlaxoSmithKline; Novartis; Onyx; Pfizer; Wyeth	GlaxoSmithKline; Pfizer; Wyeth		
Jewett, Michael A.		Novartis; Pfizer			Bayer; GlaxoSmithKline; Novartis; Pfizer; Wyeth		
Jones, Peter A.		Epigenomics; Lilly	Epigenomics	Lilly; Merck			

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Kamat, Ashish M.		Biosite (U)		Endo Pharmaceuticals; Precision Therapeutics	Bioniche Life Sciences; Biosite		
Kelly, William Kevin		Bristol-Myers Squibb; Genentech; sanofi-aventis		sanofi-aventis	Bristol-Myers Squibb; CuraGen; Genentech; ImClone Systems; Onyx; sanofi-aventis		
Klein, Eric A.‡				GlaxoSmithKline	Abbott Laboratories; Genomic Health		
Kuban, Deborah A.†		Calypso Medical		Calypso Medical			
Lee, Cheryl T.							
Lee, W. Robert†‡							
Lerner, Seth P.†		Imalux; Pfizer; Tengion			Bristol-Myers Squibb; Cell Genesys; Imalux; Lilly; Pfizer; Photocure		
Motzer, Robert J.		Aveo; Novartis		Novartis	GlaxoSmithKline; Novartis; Pfizer; Wyeth		
Moul, Judd W.		AstraZeneca; GlaxoSmithKline; Theralogix	AstraZeneca; Johnson & Johnson; Novartis; Pfizer	AstraZeneca; Pfizer; sanofi-aventis			
Nathanson, Katherine L.							
Nelson, Joel B.		Abbott Laboratories; Amgen; AstraZeneca; Millennium; Takeda		AstraZeneca; ICON			
Pollack, Alan†				Calypso Medical			
Reuter, Victor E.							
Ritter, Mark A.†				Tomotherapy	Amgen		
Roach, Mack		CareCore; Molecular Insight Pharmaceuticals		Siemens	GlaxoSmithKline		Molecular Insight Pharmaceuticals
Russo, Paul†		Willex					
Ryan, Charles J.				sanofi-aventis			
Sandler, Howard M.†		ITA Partners; Millennium; sanofi-aventis	Biogen Idec; Tomotherapy	AstraZeneca; sanofi-aventis			

## 2010 FACULTY DISCLOSURE INDEX

Name	Employment or Leadership Position	Consultant or Advisory Role	Stock Ownership	Honoraria	Research Funding	Expert Testimony	Other Remuneration
Scher, Howard I.		AstraZeneca; Veridex		Veridex	Bristol-Myers Squibb; Cougar Biotechnology; Genentech; Medivation; Novartis; Veridex		
Silverman, Stuart G.							
Skinner, Eila C.							
Smith, Matthew R.		Amgen; Cougar Biotechnology (U); GTx; Novartis					
Stevens, Lesley A.							
Tindall, Donald J.		sanofi-aventis			Adherex; NS Pharma; sanofi-aventis; Taiho		
van Poppel, Hein		Antigenics; AstraZeneca; Bayer; Cougar Biotechnology; Ferring; Gen-Probe; Pfizer; sanofi-aventis; Wyeth					
Vogelzang, Nicholas J.‡		Allos Therapeutics; Ambit; Amgen; Bayer; Celgene (U); Genentech; Keryx; Novartis; Onyx; Pfizer; Wilex		Amgen; ArQule; Bayer; Clinical Care Options; Cougar Biotechnology; Genentech; Imedex; Lippincott, Williams and Wilkins; Novartis; Onyx; Pfizer; Wyeth	Argos Therapeutics; ArQule; AstraZeneca; Cougar Biotechnology; Endocyte; GlaxoSmithKline; Keryx; Medarex; Novartis; Pfizer; Wilex		
Williams, Scott G.†							
Wood, Christopher G.†		Antigenics; Pfizer		Antigenics; Pfizer			
Zagoria, Ronald J.†				Covidien	Covidien		
Zietman, Anthony							